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Abstract:  Asrin Tengah, Nawazish-i-Husain Syed, Siti Tajidah Abdul Talip, Siti Nur Basirah 
Bujang and Charles Kennedy. Comparison of signalling mechanisms underlying UTP-evoked 
vasoconstriction of pulmonary and systemic-like arteries 
  
The endogenous nucleotide, UTP, acts at smooth muscle P2Y receptors to constrict rat pulmonary 
and tail arteries, but the underlying signalling pathways are poorly understood. The aim was to 
characterise the contribution of Ca2+ release and influx, rho kinase and protein kinase C to these 
contractions. Isometric tension was recorded from endothelium-denuded rat intralobar pulmonary 
and tail artery rings mounted on a wire myograph. Contractions were evoked by UTP and peak 
amplitude measured. Thapsigargin (1 µM), but not ryanodine (10 µM), significantly depressed 
contractions in both by 30-40% (P<0.05). Nifedipine (1 µM) significantly reduced contractions in 
tail artery by ~60% (P<0.01). Y27632 (10 µM), a rho kinase inhibitor and GF109203X (10 µM), a 
protein kinase C inhibitor, each significantly reduced pulmonary vasoconstriction by ~20%, and tail 
artery contractions by ~80% and ~40%, respectively  (P<0.01). In pulmonary artery, Y27632, 
GF109203X and thapsigargin, acted in an additive manner, but nifedipine less so. Adding all four 
together abolished the UTP response. In tail artery, Y27632 plus thapsigargin or GF109203X or 
nifedipine abolished contractions. Thapsigargin, GF109203X and nifedipine, coapplied pair-wise, 
acted additively and applying all three together abolished UTP-evoked contractions. So, Ca2+ 
release from the sarcoplasmic reticulum and influx through Cav1.2 channels, but not ryanodine 
receptors, play significant roles in UTP-evoked vasoconstriction of rat pulmonary and tail arteries. 
Rho kinase and protein kinase C are also involved, but more so in tail artery. Thus UTP activates 
multiple signalling mechanisms that lead to vasoconstriction, but their relative importance differs in 
pulmonary compared with systemic arteries. 
 




Endogenous nucleotides, such as uridine 5'-triphosphate (UTP), modulate vascular tone via P2Y 
receptors, a family of G protein-coupled receptors (GPCR) (Abbracchio et al., 2006) present 
throughout the cardiovascular system (Erlinge and Burnstock, 2008; Burnstock and Kennedy, 2011; 
Mitchell et al., 2012b: Kennedy et al., 2013). For example, we reported that UTP acts at P2Y 
receptors to contract rat isolated intralobar pulmonary (rIPA) (Chootip et al., 2002) and tail (rTA) 
(Evans and Kennedy, 1994; McLaren et al., 1998) arteries. How they produce these effects, 
however, is poorly understood. 
One possible mechanism underlying contraction is a rise in cytoplasmic [Ca2+] and 
sarcoplasmic reticulum (SR) Ca2+ stores can be released by UTP-sensitive P2Y receptors via 
coupling to Gq/11, synthesis of IP3, and activation of IP3 receptors (IP3R) (Abbracchio et al., 2006). 
Indeed, UTP evokes Ca2+ release in smooth muscle cells of many arteries, including rIPA (Guibert 
et al., 1996; Jernigan et al., 2006) and several studies have elegantly characterised sub-cellular 
changes in cytoplasmic [Ca2+], such as Ca2+ sparks and waves (Jaggar and Nelson, 2000; Zhao et 
al., 2008; Syyong et al., 2009). Ca2+ released by UTP in rIPA activates a depolarising Ca2+-
dependent, Cl- current (Hartley and Kozlowski, 1997; Chootip et al., 2005), which we showed 
causes voltage-dependent Cav1.2 Ca
2+ channels to open, enabling influx of extracellular Ca2+ and 
vasoconstriction (Mitchell et al., 2012a). In most arteries, however, the release of Ca2+ elicited by 
UTP has not been related to its vasoconstrictor actions. This is essential, as raised cytoplasmic 
[Ca2+] does not necessarily evoke contraction. For example, stimulation of the FP prostanoid 
receptor in rIPA caused IP3-dependent Ca
2+ release, but no change in vessel tone (Snetkov et al., 
2006). 
The roles of other, common signalling mechanisms have barely been studied and remain to be 
characterised fully. For example, in many tissues, Ca2+ released via IP3R stimulates ryanodine 
receptors (RyR) in the SR to elicit Ca2+-induced Ca2+ release (CICR) (Wray and Burdyga, 2010). 
Many GPCR increase the force/[Ca2+] ratio of smooth muscle contractile proteins (Ca2+-
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sensitisation) via rho kinase (RhoK) (Somlyo and Somlyo, 2003). Finally, protein kinase C (PKC), 
which is activated by UTP-sensitive P2Y receptors (Abbracchio et al., 2006), can contribute to 
vasoconstriction in several ways, including Ca2+-sensitisation (Somlyo and Somlyo, 2003; Ward et 
al., 2004), potentiation of Cav1.2 Ca
2+ currents (Ward et al., 2004; Navedo et al., 2005; Ren et al., 
2010) and inhibition of voltage-dependent K+ currents (Cogolludo et al., 2003).  
In view of the sparse and fragmentary nature of our knowledge and understanding of how 
UTP induces vasoconstriction, our aim was to develop an integrated model of the signalling 
pathways involved. The effects mediated by GPCR can vary in different vascular beds because of 
differences in their physiological function, so the actions of UTP were compared in rIPA, a low 
pressure, low resistance artery that carries deoxygenated blood away from the heart, and the rTA, a 
high-pressure systemic artery that carries oxygenated blood away from the heart.  
 
2. Materials and methods 
2.1 Tissue preparation 
The methods used conform to the ARRIVE guidelines and meet the ethical requirements of 
Strathclyde University (https://www.strath.ac.uk/science/biomedicalresearchatstrathclyde/). 
Segments of rIPA (Chootip et al., 2002) and rTA (Evans et al., 1994) were prepared for in vitro 
recording as described previously. Male Sprague-Dawley rats (200-250 g) were killed by cervical 
dislocation and exsanguination. The heart and lungs were removed en bloc and placed in a solution 
composed of (mM); NaCl 122, KCl 5, N-[2-hydroxyethyl] piperazine-N'-(2-ethanesulfonic acid] 
(HEPES) 10, KH2PO4 0.5, NaH2PO4 0.5, MgCl2 1, glucose 11, CaCl2 1.8, titrated to pH 7.3 with 
NaOH and bubbled with a gas mixture of 21% O2, 5% CO2, 74% N2. rIPA of internal diameter 300-
500 m were dissected, cleaned of connective tissue and their endothelium removed gently by 
passing a needle and thread through the lumen. They were then cut into 5 mm rings, mounted 
horizontally on a pair of intraluminal wires in 1 ml organ baths and equilibrated under a resting 
tension of 0.5 g for 60 min at 37ºC. Segments of rTA (internal diameter 300-500 m) were 
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dissected and mounted in a similar manner, but at a resting tension of 0.5-0.75 g. Tension was 
recorded with Grass FT03 isometric force transducers, connected to a PowerLab/4e system, using 
Chart 4.2 software (AD Instruments, UK).  
 
2.2 Experimental Protocols 
Drugs were added directly to the tissue bath and washed out by replacement with drug-free solution. 
Removal of the endothelium was confirmed by loss of the relaxation to acetylcholine (10 M) 
following precontraction with UTP. The UTP concentration-contraction curves in rIPA (Chootip et 
al., 2002) and rTA (Evans et al., 1994) do not reach a maximum. UTP, therefore, was applied at the 
equi-effective concentrations of 300 M and 1 mM, respectively, for 5 min at 30 min intervals, as 
preliminary experiments showed that this protocol elicited highly reproducible contractions when 
UTP was added repeatedly.  
 To investigate the role of Ca2+ release via RyR, control responses to UTP, then caffeine (10 
mM) were obtained. Ryanodine (10 µM) was added for 10 min before caffeine (10 mM) was 
readded for 5 min. After washing, ryanodine (10 µM) was added for another 10 min before 
readdition of caffeine (10 mM) for 5 min. Preliminary experiments showed that this protocol 
abolished contractions induced by caffeine. The tissues were again washed and ryanodine (10 µM) 
added for 10 min before being challenged with UTP. The effects of thapsigargin were studied in the 
same way. To determine the effects of (R)-(+)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-
cyclohexanecarboxamide dihydrochloride monohydrate (Y27632), 2-[1-(3-Dimethylaminopropyl)-
1H-indol-3-yl]-3-(1H-indol-3-yl) maleimide (GF109203X) and nifedipine, control responses to 
UTP were obtained. Arteries were then incubated with one or more of the inhibitors for 15 min 
before UTP was re-administered.  
 
2.3 Drugs and solutions 
UTP (Na3 salt), caffeine, acetylcholine chloride (Sigma, UK) and ryanodine (Calbiochem, U.S.A.) 
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were dissolved in distilled water. Nifedipine (Sigma, UK), thapsigargin, phorbol 12-myristate 13-
acetate (PMA), Y27632 and GF109203X (Tocris, U.K.) were dissolved in DMSO. Drugs were 
prepared as 10 or 100 mM stock solutions and diluted in the HEPES-based buffer before applying 
to the tissues. 
 
2.4 Data Analysis 
Contractions are expressed as mg tension or a percentage of the control response produced by UTP, 
as appropriate. Data are shown as mean ± S.E.M. of experiments on vessels from n animals and 
were compared using Student’s paired t test or one-way ANOVA with Tukey’s comparison of the 
mg tension values, as appropriate. Values of P<0.05 were considered to be statistically significant.  
 
3. Results 
3.1 Effect of ryanodine and thapsigargin 
Activation of UTP-sensitive P2Y receptors induces release of intracellular SR Ca2+ stores (Kennedy 
et al., 2013). The aim of the initial experiments was, therefore, to determine the contribution of 
these stores to the contractions elicited by UTP using ryanodine, which, at the concentration used, 
causes the RyR channels to remain in a partially conducting state and thapsigargin, which, at the 
concentration used, inhibits Ca2+ uptake into the SR (Wray and Burdyga, 2010). 
 UTP evoked contractions of rIPA (Fig. 1A,B) and rTA (Fig. 1C,D) that reached a peak within 
2-4 min. Ryanodine (10 M) abolished contractions induced by the RyR agonist caffeine (10 mM) 
(not shown), but had no significant effect on the peak amplitude of the UTP-evoked responses: rIPA 
(Fig. 1A, 2A-1st column), rTA (Fig. 1C, 2B-1st column). 
 In contrast, thapsigargin (1M), depressed significantly the responses in both tissues by 30-
40%: rIPA (P<0.01, Fig. 1B, 2A, 2nd column), rTA (P<0.05, Fig. 1D, 2B, 2nd column). Thus Ca2+ 
release from thapsigargin-sensitive SR stores plays a significant role in the UTP-evoked 
vasoconstriction in both arteries, but ryanodine-sensitive Ca2+ stores are not involved. 
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3.2 Effect of nifedipine 
We reported that the Cav1.2 Ca
2+ channel blocker, nifedipine, inhibited contractions of rIPA evoked 
by UTP by nearly 50% (Mitchell et al., 2012a). In the rTA nifedipine (1 M), a concentration that 
maximally inhibits Cav1.2 ion channels (Clapp and Gurney, 1991), significantly reduced the peak 
amplitude of the UTP response by approximately 60% (P<0.01) (Fig. 2B, 3rd column), which was 
not significantly different from its inhibitory effects in the rIPA. Thus Ca2+ influx via nifedipine-
sensitive Ca2+ channels plays a significant role in the UTP-evoked vasoconstriction in both arteries. 
 
3.3 Effect of GF109203X and Y27632 
P2Y receptors can mediate activation of RhoK and PKC (Abbracchio et al., 2006), so their 
involvement in UTP-evoked contractions was investigated using Y27632, an inhibitor of RhoK 
(Uehata et al., 1997), and the PKC inhibitor, GF109203X (Toullec et al., 1991). Initial experiments 
determined an effective concentration of GF109203X and the selectivity of Y27632. The PKC 
activator, PMA (10 M), induced very slowly developing contractions of the rIPA of variable 
amplitude (range = 58 - 390 mg) that in most cases reached a peak (168 ± 20 mg, n=18) within 60 
min and were maintained for at least another 30 min (Fig. 3A-E). These were partially suppressed 
by 3 M GF109203X (Fig. 3A) and abolished by 10 M GF109203X, added 15 min before (Fig. 
3B) or 60 min after (Fig. 3C) PMA. In contrast, Y27632 (10 M), a concentration that produces 
near maximal inhibition of RhoK (Uehata et al., 1997; Davies et al., 2000), had no effect on the 
PMA response under the same conditions (Fig. 3D,E), indicating a lack of effect on PKC. 10 M 
Y27632 and GF109203X were, therefore, used in subsequent experiments. 
 Y27632 (10 M) significantly reduced the peak amplitude of contractions evoked by UTP by 
about 20% in rIPA (P<0.01, Figs. 2A-3rd column, 4A) and by more than 80% in rTA (P<0.01, Figs. 
2B-4th column, 4B) and the inhibition was significantly greater in the rTA (P<0.001). GF109203X 
(10 M) also significantly reduced the peak amplitude of the UTP response in rIPA by over 20% 
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(P<0.01, Fig. 2A-4th column) and by around 40% in rTA (P<0.001, Fig. 2B-5th column). Inhibition 
was again significantly greater in rTA (P<0.05). Thus Y27632 and GF109203X both inhibit UTP-
evoked contractions in both arteries, but more so in the rTA. 
 
3.4 Combined inhibition of signalling components in rIPA 
These data, together with our published data (Chootip et al., 2005; Mitchell et al., 2012a) show 
clearly that multiple signalling components contribute to UTP-evoked vasoconstriction and that 
their relative contributions are artery-specific. The next experiments investigated how the individual 
components combine, by applying two or more of the inhibitors together, first in the rIPA. 
 Adding Y27632 (10 M) plus GF109203X (10 M) significantly reduced UTP contraction 
peak amplitude by about 45% (P<0.01) (Fig. 5A-1st column), which was significantly greater than 
the effect of either agent alone (P<0.05) and virtually equivalent to the sum of their individual 
effects. When thapsigargin (1 M) was added along with Y27632 (10 M) and GF109203X (10 
M), the inhibitory effects of the three drugs also appeared to be additive, as the peak response was 
significantly depressed by around 85% (P<0.01) (Fig. 5A-2nd column). This was significantly more 
than the inhibition produced by Y27632 plus GF109203X (P<0.001).  
 Nifedipine (1 M) inhibited UTP contractions in rIPA by around 45% (Mitchell et al., 2012a) 
and co-adding it with Y27632 (10 M) plus GF109203X (10 M) significantly reduced the peak 
UTP response by nearly 70% (P<0.01) (Fig. 5A-3rd column). Although this was significantly 
greater than that produced by Y27632 plus GF109203X (P<0.05), the inhibitory effects of the three 
drugs were less than additive. 
 Finally, adding all four inhibitors together abolished the response to UTP (Figs. 5A-4th 
column, 5B). Thus all of the signalling components targeted by these inhibitors are involved in 
UTP-evoked contractions of rIPA and in a partly additive and overlapping manner. 
 
3.5 Combined inhibition of signalling components in rTA 
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The data reported above in the rTA show that Y27632 has by far the greatest inhibitory effect on 
UTP-evoked contractions. The mediator(s) of the Y27632-resistant component was, therefore, 
investigated next. The contractions elicited by UTP were abolished by coapplying Y27632 (10 M) 
with nifedipine (1 M) (Fig. 6A,B-1st column. thapsigargin (1 M) (Fig. 6B-2nd column) or 
GF109203X (10 M) (Fig. 6B-3rd column). 
 Finally, thapsigargin, GF109203X and nifedipine were coapplied in the absence of Y27632. 
Each pair significantly inhibited UTP-evoked contractions and in an approximately additive 
manner. Thus in the presence of the two least effective inhibitors, thapsigargin (1 M) plus 
GF109203X (10 M), nearly 30% of the peak response to UTP remained (P<0.01) (Fig. 6B-4th 
column), while coapplication of thapsigargin (10 M) plus nifedipine (1 M) (P<0.01) (Fig. 6B-5th 
column) or GF109203X (10 M) plus nifedipine (1 M) (P<0.01) (Fig. 6B-6th column) 
substantially depressed the UTP response, but did not abolish it. In each case the inhibition was 
significantly greater than the effect of either inhibitor alone (P<0.05- thapsigargin plus GF109203X; 
P<0.001- thapsigargin plus nifedipine; P<0.001- GF109203X plus nifedipine). Applying all three 
inhibitors together abolished UTP-evoked contractions (Fig. 6B-7th column). 
 
4. Discussion 
In this study, the vasoconstriction of rIPA and rTA induced by UTP was inhibited by a similar 
amount by thapsigargin, but unaffected by ryanodine, indicating that release of SR Ca2+ stores via 
IP3R plays a role in the contractions, but RyR are not involved. Ca
2+ influx via Cav1.2 ion channels 
also contributes to the response in both arteries and to a similar extent. Contractions were also 
suppressed by inhibitors of RhoK and PKC, but significantly more so in the rTA. Simultaneously 
inhibiting two or more of these signalling components depressed the contractions in a vessel-
specific manner. Thus these data indicate that stimulation of P2Y receptors by UTP activates 
multiple signalling mechanisms that lead to vasoconstriction, but their relative contributions differ 
in pulmonary, compared with systemic, arteries. 
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4.1 Signalling mechanisms underlying UTP-evoked vasoconstriction of rIPA 
In this study, pretreatment with thapsigargin, a SERCA inhibitor that depletes SR Ca2+ stores (Wray 
and Burdyga, 2010), inhibited the peak amplitude of vasoconstriction elicited by UTP by around 
40%, showing for the first time that Ca2+ release from the SR contributes substantially to UTP-
evoked contractions of rIPA. This is important, as GPCR-mediated Ca2+ release does not always 
result in vasoconstriction (Snetkov et al., 2006). Ryanodine, at a concentration that abolished 
caffeine-induced contractions, had no effect on the UTP-evoked contractions, indicating that Ca2+-
induced Ca2+ release via RyR was not involved in the UTP response. The role of RyR in GPCR-
mediated pulmonary vasoconstriction is very variable. A similar lack of involvement was seen in 
1- and 5-HT2A-receptor-mediated contractions of dog IPA (Jabr et al., 1997; Wilson et al., 2005), 
but depleting ryanodine-sensitive Ca2+ stores partially reduced noradrenaline-evoked 
vasoconstriction of rIPA (Zheng et al., 2005) and abolished contractions of rabbit IPA by PGF2 
(Dipp et al., 2001) and mouse IPA by 5-HT (Perez and Sanderson, 2005).  
The lack of effect of ryanodine in the present study indicates that UTP elicits release of Ca2+ 
via IP3R in rIPA, consistent with the coupling of UTP-sensitive P2Y receptors to Gq/11 
(Abbracchio et al., 2006). We reported that UTP activates a Ca2+-dependent Cl- current in rIPA 
myocytes (Chootip et al., 2005) and that blocking this current depressed the peak of the UTP-
evoked vasoconstriction by almost half (Mitchell et al., 2012a). Furthermore, the contractions 
evoked by UTP were depressed by nifedipine by a similar amount and concomitant blockade of Cl- 
and Cav1.2 ion channels produced no further inhibition. Our current working model is, therefore, 
that the major function of Ca2+ released from the SR is to activate the Ca2+-dependent Cl- current, 
which depolarises rIPA smooth muscle cells, causing Cav1.2 ion channels to open and extracellular 
Ca2+ to flow into the cell and cause contraction (Fig. 7A).  
 These experiments show that the selective inhibitor, Y27632 (Uehata et al., 1997; Davies et 
al., 2000), depressed the contractions by about 20%, indicating that RhoK likely contributes to the 
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UTP response (Fig. 7A). This is a relatively minor effect compared with that seen against responses 
evoked by other GPCR in pulmonary arteries. For example, Y27632 inhibited by 70% or more, TP 
receptor-mediated contractions of rat (Martin et al., 2004), rabbit (Fu et al., 1998) and cow (Alapati 
et al., 2007) IPA and 1-adrenoceptor-mediated vasoconstriction of dog IPA (Janssen et al., 2001), 
whilst contraction of rIPA induced by sphingosylphosphorylcholine (Thomas et al., 2005) and of 
the mouse perfused pulmonary vascular bed by sphingosine 1-phosphate (Szczpaniak et al., 2010) 
were both depressed by about 65%. RhoK induces vasoconstriction by Ca2+-sensitisation (Somlyo 
and Somlyo, 2003) and consistent with this mechanism, Y27632 virtually abolished UTP 
contractions in permeabilised pulmonary arteries (Jernigan et al., 2004).  
 This study also demonstrated that GF109203X, the selective PKC inhibitor (Toullec et al., 
1991), depressed the peak contraction amplitude by about 20%, indicating a contribution of PKC to 
the UTP response. This is less than the contribution of PKC to TP receptor-mediated contraction of 
rIPA (~50%) (Cogolludo et al., 2003), but similar to that of 1-adrenoceptor-mediated 
vasoconstriction of dog IPA (Damron et al., 2002). Like RhoK, PKC can induce vasoconstriction 
via Ca2+-sensitisation (Somlyo and Somlyo, 2003; Ward et al., 2004), but this is unlikely to be its 
mode of action here, as the inhibitory actions of GF109203X and Y27632 were additive, suggesting 
separate sites of action. Consistent with this, GF109203X had no effect on UTP-evoked 
contractions in permeabilised pulmonary arteries (Jernigan et al., 2004). PKC-dependent 
phosphorylation of IP3R (Narayanan et al., 2012) is also unlikely to be involved, as using 
thapsigargin to deplete SR Ca2+ stores produced an additive effect with inhibition of PKC and 
RhoK, suggesting that these three signalling components are arranged in parallel, rather than in 
series in rIPA.  
 The cellular target(s) of PKC in rIPA remain to be determined and possibilities include Cav1.2 
ion channels (Fig. 7A), the activity of which can be potentiated by GPCR. For example, in rIPA, 
sphingosylphosphorylcholine increased Ca2+ influx via Cav1.2 ion channels in a PKC-dependent 
manner (Snetkov et al., 2008). These channels may also be constitutively phosphorylated by PKC, 
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increasing their basal activity (Navedo et al., 2005) and opening in response to depolarisation (Ren 
et al., 2010). PKC can also increase Cav1.2 ion currents indirectly by inhibiting voltage-dependent 
K+ currents in pulmonary arterial smooth muscle (Cogolludo et al., 2003), so inducing 
depolarisation and Cav1.2 ion channel opening. Indeed, endothelin-1 depolarised rIPA smooth 
muscle cells by inhibiting voltage-dependent K+ channels (Salter and Kozlowski, 1996) via 
activation of PKC (Shimoda et al., 1998). In the present study, blocking Ca2+ influx via Cav1.2 ion 
channels was less than additive with inhibition of PKC and RhoK, indicating that Cav1.2 ion 
channels are arranged at least in part in series with PKC and/or RhoK.  
 
4.2 Signalling mechanisms underlying UTP-evoked vasoconstriction of rTA 
The present experiments show that in rTA, as in rIPA, release of Ca2+ from SR stores and influx of 
extracellular Ca2+ via Cav1.2 ion channels both contribute to UTP-evoked contractions (Fig. 7B), 
but RyR are not involved. RyR also play no role in UTP-elicited contractions of rat basilar artery 
(Syyong et al., 2009). Influx of extracellular Ca2+ is important in the rTA, as nifedipine inhibited 
UTP vasoconstriction by about 60%, consistent with the depressant effect of Ca2+-free buffer 
(McLaren et al., 1998). Cav1.2 ion channel blockers likewise depressed UTP contractions of rat 
cerebral artery (Luykenaar et al., 2003) and rat (Welsh and Brayden, 2001) and dog (Matsumoto et 
al., 1997) coronary arteries. Unlike rIPA, where the inhibitory effects of thapsigargin and nifedipine 
were similar, the inhibitory effect of nifedipine in rTA was twice that of thapsigargin, indicating 
that Ca2+ release is not the only stimulus that opens Cav1.2 ion channels in this artery (Fig. 7B). The 
identity of the other stimulus is, at present, unclear, but interestingly, UTP activated a maintained, 
depolarising cation current and inhibited voltage-dependent K+ currents in rat coronary artery 
(Welsh and Brayden, 2001) and depolarised rat cerebral artery smooth muscle cells by inhibiting a 
voltage-dependent K+ current in a RhoK-dependent, PKC-independent manner, leading to 
vasoconstriction (Luykenaar et al., 2003).  
 By far the biggest differences seen in the present study were the much greater effects of 
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Y27632 and GF109203X in rTA compared with rIPA. Y27632 depressed the peak response to UTP 
in rTA by over 80%, compared with about 20% in rIPA. To the best of our knowledge, the only 
other analogous study was in rat cerebral artery, where Y27632 abolished UTP-evoked contractions 
(Luykenaar et al., 2003). UTP, however, induced translocation of RhoA to the plasma membrane of 
smooth muscle cells in rat aorta (Sauzeau et al., 2000) and mesenteric artery (Nelson et al., 2008), 
an essential step in the activation of RhoK (Somlyo and Somlyo, 2003), so stimulation of RhoK by 
UTP in vascular smooth muscle is likely to be common (Fig. 7B).  
 GF109203X also depressed the peak amplitude of UTP-evoked contractions by twice as much 
in rTA than rIPA. Again, there are few reports on the role of PKC in UTP-evoked vasoconstriction 
in other arteries, but inhibition did not affect the response to UTP in rat cerebral artery (Luykenaar 
et al., 2003). Nonetheless, as UTP-sensitive P2Y receptors couple to Gq/11, stimulation of PKC by 
UTP in vascular smooth muscle is likely to be widespread and to play a role in rTA (Fig. 7B). As 
discussed above for rIPA, the cellular target(s) of PKC in the rTA remain to be determined. The 
component of the contraction of rTA that was resistant to Y27632 was abolished by inhibiting 
individually Ca2+ release, Ca2+ influx via Cav1.2 ion channels or PKC and in each case the 
inhibition was less than additive. In addition, blocking these three components together, in the 
absence of Y27632, also abolished the response to UTP. This indicates that there is substantial 
overlap of these signalling pathways in rTA. 
 
5. Conclusions 
In conclusion, these data have developed our knowledge and understanding of how UTP causes 
arteries to contract. They show that multiple signalling mechanisms are involved in UTP-evoked 
vasoconstriction of rIPA, a low pressure, low resistance artery, and rTA, a high pressure, systemic 
artery and reveal differences in their relative roles. Whilst the contributions of Ca2+ release from 
intracellular stores and Ca2+ influx via Cav1.2 Ca
2+ channels are similar in the two arteries, PKC and 
particularly RhoK,  play a much greater role in the systemic artery. How the individual signalling 
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components interact with each other also differs in the two systems. The limited number of reports 
on the signalling mechanisms underlying UTP’s actions in other systemic arteries are in broad 
agreement with the data obtained in the rTA, but it is too early to say if they represent a general 
model of UTP signalling in systemic arteries. Finally, on the basis of our improved understanding 
of how UTP acts, further studies are now underway to investigate in greater detail how individual 
components are activated and how they interact with each other and with other potential 
mechanisms, such as voltage independent Ca2+ influx. Together, this will build a comprehensive 
and integrated model of the signalling pathways that couple P2Y receptor activation by UTP to 
vasoconstriction. 
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Fig. 1. The role of SR Ca2+ stores in contractions evoked by UTP.  
The superimposed traces show typical contractions of isolated, endothelium-denuded (A,B) rIPA 
evoked by UTP (300 M) and (C,D) rTA evoked by UTP (1 mM) before (upper traces) and after 
(lower traces) incubation with ryanodine (10 M) or thapsigargin (1 M) for 15 min. UTP was 




















Fig. 2. Inhibition of contractions evoked by UTP. 
The mean peak amplitude of UTP-evoked contractions of isolated, endothelium-denuded (A) rIPA 
in the presence of ryanodine (10 M) (n=6), thapsigargin (1 M) (n=8), Y27632 (10 M) (n=5) and 
GF109203X (10 M) (n=7), and (B) rTA in the presence of ryanodine (10 M) (n=4), thapsigargin 
(1 M) (n=4), nifedipine (1 M) (n=6), Y27632 (10 M) (n=4) and GF109203X (10 M) (n=5), 
expressed as a percentage of control responses, is shown. The numbers in brackets show n for each. 
Vertical lines show S.E.M.. * P<0.05, ** P<0.01 for responses in the presence of inhibitor 






















Fig. 3. Inhibition of contractions evoked by PMA. 
 The traces show typical responses of isolated, endothelium-denuded rIPA when (A) GF109203X (3 
M) was added 15 min before PMA (10 M); or GF109203X (10 M) was added (B) 15 min 
before or (C) 60 min after PMA (10 M); or Y27632 (10 M) was added (D) 15 min before or (E) 
60 min after PMA (10 M). GF109203X and Y27632 were applied as indicated by the open bars 














Fig. 4. Inhibition by Y27632 of contractions evoked by UTP.  
The superimposed traces show typical contractions of isolated, endothelium-denuded (A) rIPA 
evoked by UTP (300 M) and (B) rTA evoked by UTP (1 mM) before (upper traces) and after 
















Fig. 5. Combined application of inhibitors in rIPA. 
(A) The mean peak amplitude of contractions of isolated, endothelium-denuded rIPA evoked by 
UTP (300 M) in the presence of  thapsigargin (1 M) (n=5), nifedipine (1 M) (n=5), Y27632 (10 
M) (n=4) and GF109203X (10 M) (n=4), in combination and expressed as a percentage of 
control responses, is shown. The numbers in brackets show n for each. Vertical lines show S.E.M. 
** P<0.01 for responses in the presence of inhibitors compared to control. # P<0.05 for responses in 
the presence of Y27632 plus GF109203X compared to either drug alone. † P<0.05 for responses in 
the presence of nifedipine, Y27632 and GF109203X compared to Y27632 plus GF109203X. ††† 
P<0.001 for responses in the presence of thapsigargin, Y27632 and GF109203X compared to 
Y27632 plus GF109203X. 
(B) The superimposed traces show typical contractions evoked by UTP (300 M) before (upper 
trace) and after (lower trace) incubation with Y27632 (10 M), GF109203X (10 M), thapsigargin 















Fig. 6. Combined application of inhibitors in rTA. 
(A) The superimposed traces show typical contractions of isolated, endothelium-denuded rTA 
evoked by UTP (1 mM) before (upper trace) and after (lower trace) incubation with Y27632 (10 
M) and nifedipine (1 M) for 15 min. UTP was applied as indicated by the solid bar. (B) The 
mean peak amplitude of contractions evoked by UTP (1 mM) in the presence of Y27632 (10 M), 
nifedipine (1 M), thapsigargin (1 M) and GF109203X (10 M), in combination and expressed as 
a percentage of control responses, is shown. The numbers in brackets show n (4 or 5) for each. 
Vertical lines show S.E.M. ** P<0.01 for responses after treatment compared to control. † P<0.05 
for responses in the presence of thapsigargin and GF109203X compared to either agent alone. ††† 
P<0.001 for responses in the presence of nifedipine plus thapsigargin or GF109203X compared to 













Fig. 7. P2Y signalling pathways in rIPA and rTA. 
The schematics show our current understanding of the signalling pathways that mediate 
vasoconstriction evoked by UTP in (A) rIPA and (B) rTA. The signalling components that appear to 
play major roles are shown in black and less important components aer shown in blue italics. 
Abbreviations are the same as in the main body of text. PLC = phospholipase C, Depol = 
depolarisation, VC = vasoconstriction, DAG = diacyl glycerol 
 
